What's in Aldeyra Therapeutics, Inc.'s pipeline?

Aldeyra Therapeutics, Inc. has 10 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Aldeyra Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Alexion Pharmaceuticals, Inc., BRIM Biotechnology Inc., BioCis Pharma Ltd, BioCryst Pharmaceuticals, CSL Behring.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aldeyra-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Aldeyra Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aldeyra Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 7 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Monthly ADX-2191 injection	Monthly ADX-2191 injection	phase 3	Reactive aldehyde scavenger	Reactive aldehyde species (RAS)	Ophthalmology
Vehicle of ADX-102 Topical Dermal Cream	Vehicle of ADX-102 Topical Dermal Cream	phase 3	Complement inhibitor	Complement component 3 (C3)	Ophthalmology, Dermatology
ICM ADX-2191 injection	ICM ADX-2191 injection	phase 3	Aldehyde modulator	Aldehyde dehydrogenase (ALDH) / reactive aldehydes	Immunology
Vehicle Ophthalmic Solution QID to BID	Vehicle Ophthalmic Solution QID to BID	phase 3			Ophthalmology
Vehicle of ADX-102 Ophthalmic Drops	Vehicle of ADX-102 Ophthalmic Drops	phase 3	ROS scavenger / Antioxidant	Reactive oxygen species (ROS)	Ophthalmology
Vehicle Opthalmic Solution	Vehicle Opthalmic Solution	phase 3			Ophthalmology
Vehicle Ophthalmic Solution QID	Vehicle Ophthalmic Solution QID	phase 3			Ophthalmology

Therapeutic area mix

Ophthalmology · 6
Dermatology · 1
Immunology · 1
Ophthalmology, Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alexion Pharmaceuticals, Inc. · 1 shared drug class
BRIM Biotechnology Inc. · 1 shared drug class
BioCis Pharma Ltd · 1 shared drug class
BioCryst Pharmaceuticals · 1 shared drug class
CSL Behring · 1 shared drug class
Haaglanden Medical Centre · 1 shared drug class
InflaRx GmbH · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aldeyra Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Aldeyra Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aldeyra-therapeutics-inc. Accessed 2026-05-17.